Ideaya Biosciences has reported positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma, or UM, as well as a successful Type C meeting with the Food and Drug ...
Ideaya Biosciences has reported positive interim Phase 2 clinical trial data for darovasertib in neoadjuvant uveal melanoma, or UM, as well as a successful Type C meeting with the Food and Drug ...
Global Biosimilar Market is valued at approximately USD 29.4 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 17.8% over the forecast period 2024-2032. Read the ...
Global mRNA Vaccines and Therapeutics Market is valued at approximately USD 46.8 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 16.5% over the forecast period ...